Vidiia Partners with Synnovis and the University of Surrey on Groundbreaking Aspergillus Detection Project Guildford, UK – 20 June 2025 – Vidiia, a leading innovator in molecular diagnostics and AI driven testing platforms, is excited to announce the launch of a new collaborative project with Synnovis, a trusted pathology services provider, and the University of Surrey, renowned for its excellence in health and bioscience research. The partnership will focus on advancing rapid and accurate diagnostics for Aspergillus, a common, but potentially life-threatening fungal pathogen of humans and animals. This pioneering project brings together cutting-edge technology, clinical insight, and academic rigour to address the urgent need for faster, decentralised and reliable detection of Aspergillus infections, particularly in immunocompromised patients. The collaboration aims to evaluate and accelerate the development of Vidiia’s AI-powered VH Platform and Rapid Extraction technologies, optimised for use in both clinical and research settings.

About Aspergillus "Aspergillosis is a disease caused by a type of mould (fungus). The illnesses resulting from Aspergillus infection usually affect the respiratory system, but their signs and severity vary greatly. The mould that triggers the illnesses, Aspergillus, is everywhere — indoors and outdoors. Most strains of this mould are harmless, but a few can cause serious illnesses when people with weakened immune systems, underlying lung disease or asthma inhale their fungal spores. In some people, the spores trigger an allergic reaction. Other people develop mild to serious lung infections. The most serious form of aspergillosis — invasive aspergillosis — occurs when the infection spreads to blood vessels and beyond. Depending on the type of aspergillosis, treatment may involve observation, antifungal medications or, in rare cases, surgery.

" Charlie Worsley, Business Development Director at Vidiia, said: “We’re thrilled to be working alongside Synnovis and the University of Surrey on such a high-impact project. This partnership exemplifies our mission to enable earlier, smarter diagnostics using our integrated LAMP and AI platform, “AI-LAMP™” – bringing tangible benefits to patients and healthcare providers alike. This project is a significant milestone that paves the way for our platform to drive Impact"

Professor Roberto La Ragione, Interim Pro-Vice-Chancellor and Executive Dean for the Faculty of Health and Medical Sciences at the University of Surrey, added: “This collaboration provides us with the opportunity to evaluate new diagnostic technologies in a research environment with real translational potential. Faster diagnosis of Aspergillus infections could be transformative for patient outcomes, and we’re excited to contribute our expertise to this important initiative.”

Dr Adela Alcolea-Medina, Synnovis, commented: “We look forward to supporting this project and exploring how innovations like Vidiia’s platform can enhance the speed and reliability of fungal diagnostics in routine pathology workflows.”

The Aspergillus project is the latest in a series of targeted collaborations for Vidiia, whose mission is to democratise advanced molecular diagnostics through scalable hardware, robust reagents, and intelligent software tools. The outcomes of this project will inform future clinical deployment and validation studies across the UK and beyond. About Vidiia Vidiia is a UK-based molecular technology company revolutionising rapid and decentralised testing through AI-enabled platforms, rapid nucleic acid extraction, and user-friendly diagnostic workflows. Its flagship VH Platform is used in clinical, agricultural, and environmental testing across a growing number of applications. About Synnovis Synnovis is a partnership between Guy’s and St Thomas’ NHS Foundation Trust, King’s College Hospital NHS Foundation Trust, and SYNLAB UK & Ireland. It provides integrated pathology services that support both clinical excellence and innovation across the NHS and beyond. About University of Surrey The University of Surrey is a leading UK university with a global reputation for research and teaching excellence, particularly in the fields of health, biomedical sciences, and AI applications in medicine.